Aqilion announced today that the company has initiated an expanded collaborative effort with Professor Eva Särndahl and Senior Lecturer Alexander Persson at the School of Medical Sciences, Örebro…
Aqilion announced today that Johan Lund, the current Chairman of the company, will join the operational team as Chief Scientific Officer beginning on March 1. Johan Lund will mainly contribute his…
The Nomination Committee for the 2021 Annual General Meeting has been appointed and comprises the following members: Helena Arcombe, appointed by the shareholder Länsförsäkringar Skåne Christian…
AQILION AB is moving to the new Prisma office building in the Oceanhamnen neighborhood of Helsingborg. The new urban icon will be completed late this fall and Aqilion will move in to its new premises…
AQILION AB is initiating Polaris, a project aimed at developing new drug candidates, the first in their class, to prevent the harmful effects of chronic inflammation. The project will be run in close…
AQILION AB and Immunscape AB initiated a joint early project in oncology and autoimmune diseases in the spring of 2019. The point of departure was to create a drug candidate that the parties would…
AQILION AB announces TAK1 as the target of the internal drug discovery program Alnitak and will present data from the discovery phase at the international partnering event BIO-Europe® 2020 Digital…
Helsingborg, Sweden – June 10, 2020 – AQILION AB held its Annual General Meeting today on June 10, 2020, during which the Meeting resolved in accordance with the proposals set forth by the Board…
Helsingborg, Sweden – May 15, 2020 – AQILION AB announces today that the Annual Report for 2019 is now available in Swedish on the Company’s website. The report summarizes the Company’s…
Helsingborg, Sweden – May 11, 2020 – AQILION AB announced today that Torgeir Vaage has joined the company as Chief Financial Officer (CFO). Torgeir will be responsible for the finance department…
Aqilion opens a branch office at Medicon Village in Lund in order to more efficiently work and integrate with its new partners. The office also provides Aqilion with a local presence and expedites collaborative efforts with the university and the infrastructure that Lund offers a life science company.
Today AQILION AB announced that the extraordinary general meeting of the project company Trophea AB, with its wholly owned subsidiary Trophea Development AB, resolved to liquidate the companies. According to the decision, liquidation will begin on December 28, 2019.
The Nomination Committee has been appointed and comprises the following members:
Helena Arcombe, appointed by the shareholder Länsförsäkringar
Malin Ruijsenaars, appointed by the shareholders Grenspecialisten AB and LMK Forward AB
Clas Runnberg, appointed to represent other shareholders
Lena Mårtensson, appointed to represent Aqilion’s network of advisors
AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB. The purchase price is divided into a smaller amount as initial payment at the time of takeover and an additional payment based on Glactone Pharma’s future performance.
Aqilion is strengthening its portfolio with the addition of two innovative preclinical projects, Alhena and Alnitak. The company is overseeing the two pharmaceutical projects, which both fall under Aqilion’s new focus area: inflammation at the interface of oncology and immunology.
Today AQILION AB announced that the extraordinary general meeting of the project company Adenovir Pharma AB resolved to liquidate the company. According to the decision, liquidation will begin on…
Martin Johansson holds a doctorate in organic chemistry from Lund University, Sweden, where he is currently an Associate Professor at the Center for Analysis and Synthesis. He has almost 20 years’…
In March of 2018, AQILION AB (formerly Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) carried out a directed issue of “units.” Each unit consisted of one (1) share and…
Aqilion searches for early innovative pharmaceutical projects thatare based on solid research resting on a firm biological foundation and offering both clinical relevance and patient benefit….
The project company Belina is running an innovative project in early phase and is developing a product for treatment of breast cancer.After changing its strategy and organization in 2018, Aqilion…
Today the company Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB is changing its name to AQILION AB. The name change marks a new phase in the development of the company, with…
Combe has announced that it is terminating the license agreement because the company has changed its priorities and strategy for its development projects. Laccure will take the product back and…
In collaboration with researchers at Vancouver Prostate Centre in Canada, Glactone Pharma has discovered a novel way of enhancing the effects of current prostate cancer treatments. The research,…
Oncorena Holding AB today announces that the company through a share issue has raised capital to build its organization and resources in preparation for clinical development with a patient study of a…
The Danish Medicines Agency and the Ethics Committee in Region Sjaelland have both given Trophea Development approval to initiate the first clinical study, a Phase I study, with an innovative…
Oncorena AB announces that a new full-time CEO has been appointed effective July 1.
Lars Grundemar will lead the company in the intense development phase ahead.
On July 1, 2018 Fredrik Lindgren will assume the position of Chief Business Officer (CBO) at PULS. In his new role Fredrik will work with strategic and operational business development of the PULS portfolio, as well as contribute with support to the development of the individual project companies.
Glactone Pharma, in collaboration with researchers from Karolinska Institutet and Lund University, has been awarded a SEK 1,000,000 (approx. USD 115,000) grant from Swelife and Medtech4health. Glactone Pharma’s project, STAT3 inhibition as immunotherapy for the treatment of prostate cancer, aims to investigate the mechanism behind the combination effect of STAT3 inhibition and immunotherapy.
In strong competition and after external examination, Glactone Pharma has been awarded a SEK 886,500 grant (approx. USD 106,000) from Vinnova (Sweden’s Innovation Agency) in the second phase of a program aimed at innovative startup companies. The funded project will be used to characterize Glactone Pharma’s lead STAT3 inhibitor, a potential new drug for the treatment of cancers.
Glactone Pharma has been granted a Swedish patent covering novel synthetic analogs of the STAT3 inhibitor GPA500 with improved druglike properties. Glactone Pharma is actively profiling small-molecule inhibitors of STAT3 as a potential new immunotherapy and for the treatment of drug resistant cancers.
In strong competition and after external examination, Glactone Pharma has been awarded a Vinnova (Sweden’s Innovation Agency) grant for innovative startup companies. The funded project will further investigate STAT3 as a target for cancer immunotherapy.
Leading contract development and manufacturing organisation (CDMO) Recipharm is entering into a collaboration with Laccure AB for the commercial manufacture and delivery of Laccure® Pessary.
Oncorena Holding AB today announces that the company at an extra shareholder’s meeting decided to strengthen the board following the capitalization earlier this autumn.
Oncorena Holding AB today announces that the company through a new share issue has secured capital to conduct clinical studies of a completely new treatment principle for kidney cancer.
During August and September AcuCort AB implemented a preferential new share issue amounting to MSEK 6, which was over-subscribed. The share issue was implemented in order to provide capital for the operations and to broaden the ownership in preparation for a planned listing in 2017.
Adenovir Pharma is pleased to announce that the company has performed a new share issue totaling MSEK 5.5 and that the company has started its exit process. The company develops a pharmaceutical…
Glactone Pharma will participate at the American Association of Cancer Research (ACCR) Annual meeting which is one of the largest and most important events in the world for researchers in the…
Glactone Pharma is pleased to announce that the company’s recent preferential rights issue was fully subscribed. The capital injection will be used for further development of the company’s unique…
Adenovir Pharma´s patent applications relating to its novel “antiviral compound” (APD-209) for treatment of the serious and very contagious eye infection, epidemic keratoconjunctivitis (EKC),…
Glactone Pharma is pleased to announce the appointment of leading experts to its newly formed Scientific Advisory Board. The board will provide guidance and expertise that further strengthens the company’s research and development portfolio.
A Swedish research group has published scientific discoveries concerning the serious infectious eye disease EKC (epidemic keratoconjunctivitis) in the prestigious journal Acta Ophthalmologica.The researchers have shown that patients exhibit more severe symptoms and clinical findings in EKC caused by some specific adenoviruses.
Martin Johansson, CEO of Glactone Pharma AB, to present at Biotech Showcase™. “Investors and biopharmaceutical executives from around the world gather in San Francisco during this week and…
Glactone Pharma has been awarded financing from the VINNOVA, Sweden’s Innovation Agency, for a new innovation project. The project is aimed at developing methods to design novel synthetic analogs…
The new non-prescription product Laccure® Pessary is a breakthrough women’s health product that is effective, safe and user-friendly, addressing the unmet needs of the 300 million women suffering…
A research group at Umeå University has published scientific discoveries concerning a new drug candidate for the treatment of the serious eye disease EKC in the prestigious journal Organic & Biomolecular Chemistry.
The patent relates to novel synthetic analogs of the STAT3 inhibitor GPA500 with improved properties. Glactone Pharma is actively profiling novel small-molecule inhibitors of STAT3 for the treatment…
The Swedish company Laccure AB has developed a breakthrough women’s health product that is effective, safe and user-friendly. Laccure’s owners are now aiming to divest the company to a buyer with…
Members of Glactone Pharma’s innovator group have published an article in the highly rated scientific journal European Urology: “The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer” is published in the journal European Urology, impact factor 13.938 (Eur Urol. 2015, doi:10.1016/j.eururo.2015.06.016).
Adenovir develops drugs against the contagious eye disease EKC (epidemic keratoconjunctivitis), one of which is now being tested in phase II. VINNOVA, the Swedish Government Agency for Innovation Systems, has granted Adenovir SA Development AB SEK 500,000 for the pharmaceutical development of a second generation drug for the treatment of EKC.
Adenovir Pharma has strengthened its board of directors with the addition of two new members with solid experience from the pharma industry, Karin Wingstrand and Mats Lidgard.
“It is very positive that we have managed to attract people like Karin and Mats to our board in the current phase, as we are preparing the company for an exit,” says Stefan Appelgren, chairman of the board, Adenovir.
Glactone Pharma has generated new exciting data demonstrating that the STAT3 inhibitor GPA500 reduces immunosuppressive markers on treatment resistant prostate cancer cells and that activation of the oncogenic STAT3 pathway is a mechanism of treatment resistance. The results will be published as an abstract (J Clin Oncol 33, 2015 (suppl; abstr e16075)) at ASCO.
Glactone Pharma will be presenting new exciting data at the annual meeting for AACR, on April 19, that demonstrate that the STAT3 inhibitor GPA500 suppresses the growth of prostate cancer cells resistant to second-generation anti-androgens. With GPA500 as a lead, Glactone Pharma has developed novel proprietary STAT3 inhibitors with improved drug like properties.
Glactone Pharma AB, a project company in P.U.L.S, Sweden’s leading life science incubator, is developing a drug for the treatment of metastasizing castration resistant prostate cancer. Glactone,…
The Swedish pharmaceutical development company Adenovir Pharma has raised SEK 10 million via a rights issue to fund completion of an ongoing clinical phase II study for treatment of infectious eye disease and to prepare for exit. Caused by adenoviruses, millions of people are infected every year by epidemic keratoconjunctivitis (EKC).
The Swedish pharmaceutical development company Adenovir Pharma has started a phase II clinical study for the treatment of an infectious eye disease. Caused by adenoviruses, millions of people are infected every year by epidemic keratoconjunctivitis (EKC). There are currently no effective antiviral treatments available.
Glactone Pharma AB, a project company in P.U.L.S, Sweden’s leading life science incubator, has recently issued a new round of shares of 5.5 MSEK for the continued development of their novel drug for the treatment of castration resistant prostate cancer.
Adenovir Pharma’s patent application relating to its novel compound for the treatment of the serious eye infection, epidemic keratoconjunctivitis (EKC), has been approved by the European Patent Office (EPO). Previously this patent has been approved in South Africa and is in national phase in several key markets.
Glactone Pharma is a new project company within PULS, Sweden´s largest private incubator in life science. Glactone Pharma develops a new drug against castration-resistant prostate cancer, a stage of the disease when the tumor is unresponsive to therapy with anti-hormonal drugs. This corresponds to approximately 40% of all prostate cancer patients and they lack effective treatment today.
The Swedish company Laccure AB has developed a breakthrough product for treatment and prevention of bacterial vaginosis (BV) with a proven cure rate of 80 percent already after one vaginal tablet. The product recently got CE marking as a Class IIa medical device.
DuoCort AB har ingått avtal med läkemedelsföretaget ViroPharma Incorporated om att sälja dotterbolaget DuoCort Pharma AB med dess egenutvecklade läkemedel Plenadren®, en ny behandling för binjurebarksvikt, även kallad Addisons sjukdom. Det totala avtalsvärdet uppgår till över en miljard kronor varav 220 miljoner erhålls i samband med ViroPharmas förvärv av DuoCort Pharma.
The Swedish specialty pharma company, DuoCort Pharma announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending marketing authorisation of its product Plenadren, a novel treatment for adrenal insufficiency.
LIDDS new local treatment of prostate cancer shows a clear local antiandrogen response and is well tolerated. The Swedish pharmaceutical company presented interim data from its phase IIa trial at the 26th Annual Congress of the European Association of Urology (EAU) in Vienna this weekend.
Helsingborg June 29th 2009- DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency. The release profile of DuoCort’s new form of treatment with once-a-day hydrocortisone dosing resembles the physiological secretion pattern. The data is published today in the European Journal of Endocrinology, a leading scientific journal for endocrinology.
Helsingborg/ Washington DC June 12th 2009- DuoCort gained promising data from its Phase II/III study for the rare and life threatening disease adrenal insufficiency. DuoCort’s new form of physiological treatment with once daily dosing show improved cardiovascular measures compared to standard hydrocortisone given thrice daily. The company presents the data at the ENDO congress in Washington DC.
Stanko Skrtic, Chief Scientific Officer, and Maria Forss, Head of business development, joined the PULS team of life sciences project management and drug development experts in mid August.
The board elected today two new P.U.L.S. Associate Partners, Mats Pettersson and Professor Anders Vedin